Skip to content

医療関係者向け

がん検診

早期がん発見の実証されたアプリケーション

がん検診

0%
胃癌 - GASTROClear - 2019
0%
肺癌
0%
乳癌
0%
大肠癌
0%
卵巣がん
0%
肝臓がん

GASTROClear

世界初胃がん早期発見のためのマイクロRNA血液検査

- 初期の胃がんを見つけます

- 現在シンガポールでで販売中

- 承認済み-シンガポールヘルスサイエンス庁から体外診断用医薬品承認済み,CEマーク、ISO13485の認証を取得しております。

- 初期の胃がんを見つけます(ステージ0~2)高精度で

Diagnostic solutions for infectious, cardiovascular, and metabolic diseases

0%
COVID-19 - Launched in Feb 2020 as Fortitude Kit
0%
Heart Failure
0%
Pulmonary Hypertension
0%
Sepsis
0%
Insulin Resistance

Fortitude Kit

新型コロナウイルス(SARS-CoV-2)PCR検査法

- First COVID-19 diagnostic test kit approved for use in Singapore through Provisional Authorization by Singapore's Health Sciences Authority(HSA).

- Deployed in 13 Singapore hospitals and labs and over 30 countries worldwide since February 2020. Exported to USA, Hong Kong, New Zealand, and Panama, among others.

- Can be combined with MiRXES Swab Collection System and MAGec automated RNA extraction solution for a complete end-to-end COVID-19 testing solution.

- Developed by researchers at Singapore's Agency for Science, Technology and Research (A*STAR) and Tan Tock Seng Hospital (TTSH). Technology has been licensed to MiRXES in February 2020 for mass production.

- MiRXES is a legal product owner of Fortitude Kit since March 2020.

Technical details

- A 1-step real-time RT-PCR test for detecting SARS-CoV-2 virus.

- Targets the portion of the virus genome that is less prone to mutation, enabling robust detection of the virus.

- Analytical Limit of Detection (LoD): 10 copies per reaction.

- Time from RNA to result: 90-120 minutes.

- Compatible with Bio-Rad, Applied Biosystems, and Roche real-time PCR equipment.

MiRXESは、その技術を使用いて病気を診断し、現実の問題を解決します。

Explainer Video: microRNA biomarkers for disease detection

動画再生